Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FormBlends vs Maves

By GLP-1 ScorecardUpdated

FormBlends
Site position #86

Higher grade

Maves
Site position #99

Lower grade

Score comparison

FormBlends has the higher recorded score — 72.7/100 to 71.8/100, but only just.

FormBlends grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FormBlends is a US direct-to-consumer brand selling compounded GLP-1 weight-loss medication — compounded semaglutide from $99 and compounded tirzepatide from $349 — dispensed by a licensed 503A pharmacy and fulfilled through its FormScripts telehealth portal. Maves is close behind and may still be the better fit — see the factor split below.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueEven
84
84
Dose & formulationFormBlends +12
77
65
Clinical oversightEven
76
76
Labs & monitoringEven
52
52
FulfillmentMaves +13
74
87
Contract termsEven
55
55
FormBlends · top barMaves · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricFormBlendsMaves
WeighScore72.7/10071.8/100
GradeCC
Site position#86#99
Semaglutide$99/mo (compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$349/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualNot confirmedNot confirmed
FormBlends

Site position #86 · C

Strengths

  • Low published entry price on compounded semaglutide ($99) from a licensed 503A pharmacy
  • Physician-supervised program with 24/7 care-team access and free shipping over $150
  • Extensive free educational content, guides and provider comparisons on-site

What to consider

  • Enrollment and final pricing complete on an external portal (rx.formscripts.com), not fully on-site
  • $99 may be an intro rate; tirzepatide is comparatively high at $349/mo
  • State availability and LegitScript status not published; pharmacy is its own FormScripts brand
Maves

Site position #99 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

What to consider

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard